Sanofi (NASDAQ:SNY) Given Average Rating of “Buy” by Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned a consensus recommendation of “Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $62.6667.

SNY has been the topic of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd.

Institutional Trading of Sanofi

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capital Analysts LLC boosted its position in Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after buying an additional 204 shares in the last quarter. Thomasville National Bank increased its stake in shares of Sanofi by 0.3% in the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock valued at $3,886,000 after buying an additional 211 shares during the period. Waterfront Wealth Inc. raised its holdings in Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after purchasing an additional 214 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in shares of Sanofi by 2.3% during the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after buying an additional 226 shares during the last quarter. Finally, HM Payson & Co. lifted its stake in shares of Sanofi by 3.4% in the 3rd quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock valued at $342,000 after purchasing an additional 235 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $49.66 on Friday. The stock’s 50-day moving average is $48.64 and its 200-day moving average is $49.50. The company has a market cap of $121.94 billion, a price-to-earnings ratio of 11.63, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.10. The business had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.25 earnings per share. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.